Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Improvements examine found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://anatolek134csh6.wikicorrespondence.com/user